Intratumor heterogeneity and clonal evolution in an aggressive papillary thyroid cancer and matched metastases.

57. Le Pennec S, Konopka T, Gacquer D, Fimereli D, Tarabichi M, Tomas G, Savagner F, Decaussin-Petrucci M, Tresallet C, Andry G, Larsimont D, Detours V, Maenhaut C 2015

Endocrine-related cancer 22:205-216.

Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.

48. Worden F, Fassnacht M, Shi Y, Hadjieva T, Bonichon F, Gao M, Fugazzola L, Ando Y, Hasegawa Y, Park DJ, Shong YK, Smit JW, Chung J, Kappeler C, Meinhardt G, Schlumberger M, Brose MS 2015

Endocrine-related cancer 22:877-887.

Timing of multikinase inhibitor initiation in differentiated thyroid cancer.

20. Brose MS, Smit J, Lin CC, Pitoia F, Fellous M, DeSanctis Y, Schlumberger M, Tori M, Sugitani I 2017

Endocrine-related cancer 24:237-242.

Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.

22. Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, Dutcus CE, Teng A, Gianoukakis AG, Sherman SI 2017

Endocrine 56:121-128. 2016


En visitant notre site Web, vous acceptez que nous utilisions des cookies pour vous assurer d'obtenir la meilleure expérience.